A body of evidence indicates that regulations of aberrant NF-kB and the signaling pathways that control its activity are involved in cancer development and progression, as well as in drug resistance, especially during chemotherapy and radiotherapy28, 29, 30. This evidence concerns the gene NFKB1 and cancer.